Revolution Medicines, Inc.
RVMDRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers.
Earnings
Next report
Aug 5, 2026 (In 3 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex technology platform to discover and develop small molecules that inhibit the active, GTP-bound form of RAS proteins. Its core value proposition lies in addressing elusive frontier cancer targets through sophisticated structure-based drug discovery and precision medicine approaches.
A pioneer in RAS(ON) inhibition using a proprietary tri-complex platform to target the active form of RAS, differentiating itself from first-generation KRAS(OFF) inhibitors.
Questions, answered.
- What is Revolution Medicines, Inc.'s market cap?
- Revolution Medicines, Inc. (RVMD) has a market capitalization of $40.6B and trades on NASDAQ.
- Who are Revolution Medicines, Inc.'s competitors?
- Revolution Medicines, Inc.'s key competitors include Amgen Inc., Bristol Myers Squibb, Eli Lilly, and others. These companies compete in similar markets and product categories.
- Who does Revolution Medicines, Inc. partner with?
- Revolution Medicines, Inc.'s notable partners include Bristol Myers Squibb, Amgen Inc., Summit Therapeutics, Inc., and others.
- What subsidiaries does Revolution Medicines, Inc. have?
- Revolution Medicines, Inc.'s subsidiaries include EQRx, Inc..
- Where is Revolution Medicines, Inc. headquartered?
- Revolution Medicines, Inc. is headquartered in United States of America and employs approximately 411 people. It has been publicly traded since 2020.